Victrex Maintains FY Guidance Despite Subdued Q1, Unveils Profit Improvement Plan

Victrex keeps FY 2026 guidance despite a softer Q1 start

Victrex has posted a steady-if-muted first quarter and kept full-year guidance unchanged. Volumes fell 4% in Q1, revenue slipped 6%, and average selling prices (ASP – average revenue per kilogram) were 2% lower. January, however, showed a pick-up, leaving year-to-date (YTD) volumes in line with last year.

The company continues to flag a second-half weighted year, with H1 2026 expected to be weaker than H1 2025. A currency headwind is also skewed to the first half.

Q1 2026 numbers at a glance

Metric	Q1 2026	Q1 2025	% change
Sales volume (tonnes)	858	898	-4%
Revenue (£m)	62.4	66.6	-6%
ASP (£/kg)	73	74	-2%

ASP was broadly in line with last year, down just £1/kg. The revenue drop broadly mirrors the volume decline, with a small drag from pricing and sales mix.

YTD view: January bounce steadies the ship

• YTD volumes (four months to 31 January 2026) are in line with the prior year, helped by a stronger January after a weaker December.
• YTD revenues are slightly lower, primarily due to sales mix.
• Management reiterates that FY 2026 performance will be weighted to H2, with H1 2026 expected to be weaker than H1 2025. A currency headwind is also weighted to H1.

For clarity: YTD means year to date, and H1/H2 refer to the first and second halves of the financial year. The reiteration of H2-weighting suggests management sees improvement building as the year progresses.

End-markets: Energy & Industrial leads, VARs recover, Medical still softer

The divisional colour helps explain the quarter.

• Energy & Industrial: Continued to perform well with healthy activity levels.
• Value Added Resellers (VARs – distributors who add services or components): Slower start in Q1, but momentum improved at the start of Q2. YTD volumes in VARs are now ahead of last year.
• Medical: Revenues remain slightly below the prior year YTD, though January saw the normal seasonal improvement over Q1.

Transport was more subdued in Q1, and that – together with slower VARs early on – was enough to offset Energy & Industrial strength. The early Q2 improvement in VARs is a constructive sign.

Balance sheet and dividends: cash headroom, but net debt set to rise post-dividend

Metric	Position
Net debt at 31 December 2025	£21.1m
Cash at 31 December 2025	£28m
FY 2025 final dividend	46.14p/share (c. £40m to be paid later this month)
Total FY 2025 dividends per share	59.56p

Victrex ended December with modest net debt and good liquidity. The c. £40m final dividend will be paid later this month, so net debt will increase from the £21.1m reported at 31 December.

Dividend capacity beyond this is not disclosed today, but the second-half weighting and cost actions will be key to underpinning cash generation.

Profit Improvement Plan: £10m+ annualised savings targeted

Management is moving quickly on its Profit Improvement Plan, focused on three pillars: portfolio simplification, operating efficiency and overhead costs. The target is at least £10m of annualised cost savings to be realised in FY 2027, with some initial benefits in the latter part of H2 2026.

That phasing means the P&L impact this year should be back-end loaded, dovetailing with the broader H2-weighting guidance. Further detail will come at the interim results.

Guidance and CEO message: transitional year, second-half focus

Full-year guidance is unchanged. The CEO, Dr James Routh, characterises FY 2026 as a transitional year, with an emphasis on sharpening execution and becoming more agile and customer-focused. The tone is realistic about macro risks but confident about the company’s innovation pipeline and market breadth.

For investors, the key is that despite a subdued Q1, the company still expects to make up ground later in the year. The currency headwind and a softer H1 set the bar, but operational levers and end-market normalisation are expected to lift H2.

What matters for shareholders now

• Quarterly momentum: January improved, and early Q2 VARs volumes are ahead of last year. Sustaining that into the spring will be important.
• Mix and pricing: YTD revenue is slightly lower on mix. Watch whether a stronger Energy & Industrial contribution and normalising Transport/Medical demand improve ASP and margin.
• FX drag: A currency headwind is weighted to H1. The company has not quantified it here (not disclosed), so sensitivity to rates remains a watchpoint.
• Cash and dividends: With a £40m dividend going out, keep an eye on working capital and capex discipline to steady net debt through H2.
• Cost savings delivery: Early benefits in H2 2026 and the path to at least £10m annualised savings by FY 2027 are critical to the medium-term margin story.

Josh’s take: steady guidance, credible actions, but execution test ahead

This is a sensible, no-drama update. Q1 softness is visible in the numbers, but January’s recovery and early Q2 traction in VARs support the decision to hold guidance. Energy & Industrial remains a bright spot, while Medical and Transport need to firm up to fully unlock operating leverage.

The Profit Improvement Plan looks well targeted, and the timing aligns with the stated H2 weighting. The near-term trade-off is cash out for the FY 2025 dividend, which nudges net debt higher until earnings and savings ramp. Net-net, I see this as mildly positive: guidance intact, self-help in motion, and early signs of demand stabilisation. Now it’s about delivering the second half.

Other housekeeping

• AGM is today at 11.00am GMT at JP Morgan, 1 John Carpenter Street, London EC4Y 0JP.
• Order book detail, margin guidance and capex levels are not disclosed in this update.